Literature DB >> 33649887

Evaluating Solubility of Celecoxib in Age-Appropriate Fasted- and Fed-State Gastric and Intestinal Biorelevant Media Representative of Adult and Pediatric Patients: Implications on Future Pediatric Biopharmaceutical Classification System.

Ramzi Shawahna1,2, Ahed Zyoud3, Aseel Haj-Yahia4, Raheek Taya4.   

Abstract

Prediction of performance of traditional, reformulated, and novel oral formulations in adults and pediatrics is of great importance. This study was conducted to assess solubility of celecoxib in age-appropriate fasted- and fed-state gastric and intestinal biorelevant media, classify celecoxib into biopharmaceutical classification system (BCS), and assess the effects of age-related developmental changes in the composition and volume of gastrointestinal fluids on the solubility and performance of oral formulations containing celecoxib. Solubility of celecoxib was assessed at 37°C in the pH range specified by the BCS-based criteria in 13 age-appropriate biorelevant media reflective of the gastric and proximal small intestinal environment in both fasted and fed states in adults and different pediatric subpopulations. A validated HPLC-UV method was used to quantify celecoxib. Experimental and computational molecular descriptors and in vivo pharmacokinetic data were used to assign the permeability class of celecoxib. Celecoxib belonged to BCS class 2. The pediatric to adult solubility ratios were outside the 80-125% boundaries in 3 and borderline in 1 biorelevant media. Significant age-related variability could be predicted for oral formulations containing celecoxib intended for pediatric use. Findings of this study indicated that the criteria used in the adult BCS might not be directly applied to pediatric subpopulations.

Entities:  

Keywords:  biopharmaceutical optimization; biopharmaceutics; biopharmaceutics classification system (BCS); biorelevant; gastric volume; infant; neonate; pediatric; permeability; solubility

Mesh:

Substances:

Year:  2021        PMID: 33649887     DOI: 10.1208/s12249-021-01958-3

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  63 in total

Review 1.  Paediatric oral biopharmaceutics: key considerations and current challenges.

Authors:  Hannah K Batchelor; Nikoletta Fotaki; Sandra Klein
Journal:  Adv Drug Deliv Rev       Date:  2013-11-01       Impact factor: 15.470

Review 2.  Paediatric Drug Development and Formulation Design-a European Perspective.

Authors:  Diana A Van Riet-Nales; Piotr Kozarewicz; Brian Aylward; Rutger de Vries; Toine C G Egberts; Carin M A Rademaker; Alfred F A M Schobben
Journal:  AAPS PharmSciTech       Date:  2016-06-07       Impact factor: 3.246

3.  Therapeutic orphans.

Authors:  H Shirkey
Journal:  J Pediatr       Date:  1968-01       Impact factor: 4.406

4.  Unlicensed and off-label drug use: issues and recommendations.

Authors:  Sharon Conroy
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

Review 5.  Summary of the National Institute of Child Health and Human Development-best pharmaceuticals for Children Act Pediatric Formulation Initiatives Workshop-Pediatric Biopharmaceutics Classification System Working Group.

Authors:  Susan M Abdel-Rahman; Gordon L Amidon; Ajay Kaul; Viera Lukacova; Alexander A Vinks; Gregory T Knipp
Journal:  Clin Ther       Date:  2012-11       Impact factor: 3.393

Review 6.  A report from the pediatric formulations task force: perspectives on the state of child-friendly oral dosage forms.

Authors:  Anne Zajicek; Michael J Fossler; Jeffrey S Barrett; Jeffrey H Worthington; Robert Ternik; Georgia Charkoftaki; Susan Lum; Jörg Breitkreutz; Mike Baltezor; Panos Macheras; Mansoor Khan; Shreeram Agharkar; David Douglas MacLaren
Journal:  AAPS J       Date:  2013-08-02       Impact factor: 4.009

7.  Lack of pediatric drug formulations.

Authors:  M C Nahata
Journal:  Pediatrics       Date:  1999-09       Impact factor: 7.124

8.  Considerations for a Pediatric Biopharmaceutics Classification System (BCS): application to five drugs.

Authors:  Shivani V Gandhi; William Rodriguez; Mansoor Khan; James E Polli
Journal:  AAPS PharmSciTech       Date:  2014-02-21       Impact factor: 3.246

9.  The National Institutes of Health and the Best Pharmaceuticals for Children Act.

Authors:  Anne Zajicek
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

10.  Challenges in pediatric drug development: a pharmaceutical industry perspective.

Authors:  Klaus Rose
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

View more
  1 in total

1.  Medication errors in neonatal intensive care units: a multicenter qualitative study in the Palestinian practice.

Authors:  Ramzi Shawahna; Mohammad Jaber; Rami Said; Khalil Mohammad; Yahya Aker
Journal:  BMC Pediatr       Date:  2022-05-30       Impact factor: 2.567

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.